The seroconversion rate increased after the second dose, although it was still lower in HM patients (65.3% vs. 97.8%) mainly due to low seroconversion rate in patients with CLL and B-cell leukemia/lymphoma treated with anti-CD20 antibodies or BTK inhibitors [113]. The gene discussed is BTK; the disease is lymphoma.